Renal effects of levosimendan: a consensus report

Clicks: 260
ID: 271562
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #8 of 22 articles by views in cardiovascular drugs and therapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart fail …
Reference Key
mb2013cardiovascularrenal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yilmaz MB;Grossini E;Silva Cardoso JC;Édes I;Fedele F;Pollesello P;Kivikko M;Harjola VP;Hasslacher J;Mebazaa A;Morelli A;le Noble J;Oldner A;Oulego Erroz I;Parissis JT;Parkhomenko A;Poelzl G;Rehberg S;Ricksten SE;Rodríguez Fernández LM;Salmenperä M;Singer M;Treskatsch S;Vrtovec B;Wikström G;;
Journal cardiovascular drugs and therapy
Year 2013
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.